Drug or treatment

Lorigerlimab clinical trials

As of November 12, 2026, Find a Trial lists 3 clinical trials of Lorigerlimab that are recruiting, at sites in 3 countries (most in United States (3), Canada (1), South Korea (1)). By phase: Phase 2 (3). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.

Newest trials

StudyPhaseWhereStatusRegistered
Lorigerlimab in pancreatic cancer with BRCA/RAD51 gene mutations Phase 2 Miami, Florida Recruiting May 4, 2026
Regorafenib and lorigerlimab once radiographic MRD after colorectal cancer therapy Phase 2 Houston, Texas Recruiting Jul 18, 2025
Lorigerlimab for advanced platinum‑resistant and clear‑cell gynecologic cancers Phase 2 Los Angeles, California and 15 other locations Recruiting Dec 12, 2024

All recruiting trials (3)

Quick answers

How many clinical trials of Lorigerlimab are recruiting right now?

3, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 3 countries. The most sites are in United States (3 trials), Canada (1 trial), South Korea (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 3. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →

Last reviewed 2026-11-12 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.